STAT3 as a predictive biomarker in head and neck cancer: A validation study.

Abstract

Locally advanced head and neck squamous cell carcinoma (LAHNSCC) treatment consists of radiotherapy (RT) alone or cisplatin-based concomitant chemoradiotherapy (CCRT). CCRT is accompanied by substantially more toxicity than RT alone. A previous retrospective cohort study found that LAHNSCC patients with tumors negative for nuclear expression of the signal transducer and activator of transcription 3 (STAT3) protein might not benefit from the addition of cisplatin to radiotherapy (RT) treatment. We set out to validate these results in a new cohort. We found that in patients with both STAT3 positive and negative tumors, disease-free survival (DFS) and overall survival (OS) did not differ significantly between treatment with cisplatin-based concomitant chemoradiotherapy (CCRT) and radiotherapy alone. Therefore, our validation study does not confirm that STAT3 is a potential biomarker to predict the effectiveness of the addition of cisplatin to RT in LAHNSCC patients.

• Authors: N J van Ruitenbeek, L L van der Woude, J H van Krieken, A C H van Engen-van Grunsven, A E C A B Willemsen, C M L van Herpen
• Journal: Pathology, research and practice (Pathol Res Pract) Vol. 216 Issue 11 Pg. 153172 (Nov 2020) ISSN: 1618-0631 [Electronic] Germany
• PMID: 32858373 (Publication Type: Journal Article)
• Copyright: Copyright © 2020. Published by Elsevier GmbH.

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• STAT3 Transcription Factor
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (metabolism)
• Chemoradiotherapy
• Cisplatin (therapeutic use)
• Female
• Head and Neck Neoplasms (metabolism, mortality, pathology, therapy)
• Humans
• Male
• Middle Aged
• Neoplasm Staging
• Prognosis
• Radiotherapy
• Retrospective Studies
• STAT3 Transcription Factor (metabolism)
• Survival Rate
• Treatment Outcome